Abstract: . . .  NOTES Advances in the Pharmacologic Treatment of Arteriosclerosis : What Does the Future Hold? Russell H. Samson, MD, FACS, RVT, Sarasota, FL 31st Global: Vascular and Endovascular Issues, Techniques and Horizons he last 10 years has seen an explosion in our knowledge about atherosclerosis and its risk fac- . . .
. . .  weight and stopping smoking) that can do the same thing at no cost and have other benefits as well. References 1. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant apoA-I Milano on coronary athero sclerosis in patients with acute coronary syn dromes: a randomized controlled trial. JAMA 2003;290:2292300. 2. Wald NJ, Law MR. Strategy to reduce cardiovas- cular disease by more than 80%. BMJ 2003;326:1419. XX.5.2 NOTES  . . .
. . .  non- vascular benefits include prevention of osteoporosis, Alzheimers disease, and possibly colon cancer. Current guidelines suggest using these drugs to lower LDL cholesterol below 100 mg/dL, and it is conceiv- able that we should try to lower cholesterol as low as possible. However, some patients cannot tolerate the medication because of side effects, which may be mild, such as vague muscle ache, lethargy, or memory holes, or potentially serious and lethal, such as rhab- domyolysis and hepatic dysfunction. Future more powerful statins . . .
--1766,3,294,1695,8830